标题
Switching of biologics in psoriasis: Reasons and results
作者
关键词
-
出版物
JOURNAL OF DERMATOLOGY
Volume 44, Issue 9, Pages 1015-1019
出版商
Wiley
发表日期
2017-05-10
DOI
10.1111/1346-8138.13860
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2015) Richard B. Warren et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO)
- (2014) Fabio Ayala et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study
- (2013) Karen Minde Fagerli et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry
- (2013) Bente Glintborg et al. ARTHRITIS AND RHEUMATISM
- Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study
- (2013) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug survival rates in patients with psoriasis after treatment with biologics
- (2013) Yoshinori Umezawa et al. JOURNAL OF DERMATOLOGY
- Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
- (2011) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
- (2011) Atsuyuki IGARASHI et al. JOURNAL OF DERMATOLOGY
- Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
- (2011) Bruce E. Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study
- (2011) Alice B. Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE
- (2011) J.-P. Ortonne et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
- (2010) P.P.M. Van Lümig et al. BRITISH JOURNAL OF DERMATOLOGY
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
- (2010) Hideshi Torii et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
- (2010) Akihiko ASAHINA et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
- (2010) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments
- (2009) Annamaria Mazzotta et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now